England’s health service refers ten mental health providers to regulator


NHS England’s review found consent procedures did not follow its digital principles. Its guidance calls for decisions for each patient, rather than blanket use of monitoring technology.
NHS England referred ten mental health trusts to the Care Quality Commission (CQC), England’s health regulator, after finding that their consent procedures for digital patient monitoring did not follow its digital principles, the BBC reported on 6 October. On 20 October, lawyers for bereaved families asked the Lampard Inquiry to recommend stopping Oxevision nationally on mental health inpatient wards, alleging that misuse had contributed to patient harm and deaths.
Oxevision, one of the systems covered by the review, uses infrared sensors and cameras in patients’ bedrooms to monitor breathing and pulse without staff entering the room. NHS England’s 2023 guidance said monitoring technology should not be introduced as a blanket approach: trusts should decide separately for each patient and involve that patient where possible.
The inquiry was told that five patients died by suicide or unexpectedly over two years while monitored by Oxevision at Essex Partnership University NHS Foundation Trust. These were deaths during monitoring; the lawyers’ claims that misuse contributed to deaths were submissions to the inquiry, not findings by it.
Peter Mant, a lawyer representing more than 70 bereaved families, alleged that misapplication of Oxevision had materially contributed to harm and, in some cases, deaths. His clients include the family of Elise Sebastian, 16, who died by suicide in 2021 when staff had muted the system’s alarms, according to the Guardian’s account of the submissions.
Mant said nursing staff, patients and managers were confused about how to use Oxevision. He said it had too often replaced in-person observations, missing opportunities for direct conversations and support that inquiry experts considered critical to treatment and recovery.
Brenda Campbell, another lawyer for bereaved families, represented Sophie Alderman’s family. The inquiry heard that Alderman mistakenly believed in 2022 that Oxevision would bring staff to save her. Campbell also argued that bedroom cameras invaded patients’ privacy without giving them a way to know when they were being watched.
Both lawyers asked chair Kate Lampard to recommend stopping Oxevision nationally on mental health inpatient wards. Mant also requested mandatory life-saving training for all mental health staff. Neither request amounts to an adopted suspension or an interim recommendation.
The Lampard Inquiry is examining the deaths of more than 2,000 people who spent time in mental health units in Essex between 2000 and the end of 2023. It heard that NHS England first became aware of safety concerns linked to Oxevision in 2021. Gareth Harry, NHS England’s national delivery director for mental health, learning disability and autism, said the concerns involved consent, patient observations and human rights.
An internal NHS England email from 2022 shown to the inquiry said a staff member knew of trusts where patients were “not being given the choice to refuse being filmed”.
Harry said NHS England wrote to the CQC on 2 October and shared the review’s findings with inspection teams. The ten trusts were not named. The referrals were not enforcement findings against them. A CQC spokesperson said the regulator considers information of concern and can take action when providers fall short of relevant care guidelines.
Mant challenged the effectiveness claims of Lio, Oxevision’s Oxford-based manufacturer, as based on “nothing more than unverified anecdote”. He also said the inquiry’s statisticians had found no evidence supporting its effectiveness. Those were his characterizations of the evidence.
Lio’s head of patient safety, Laura Cozens, defended the system in testimony reported on 20 October. She said the evidence should not be interpreted as showing that Oxevision was ineffective, unsafe or without benefit, and said it had helped staff intervene in critical safety incidents.
In July testimony, Cozens had said the technology needed to be properly explained to patients. She also said it had helped prevent serious incidents, including falls on a dementia ward. These assessments of its benefits came from the manufacturer.
The BBC’s 6 October report had scheduled CQC evidence for 7 October. Lampard is considering interim action concerning Oxevision and has said she could issue recommendations if she identifies urgent patient-safety concerns before the final report, due in 2028. The families’ requests now await her decision.
Regulator records describe oil and chemical releases. A September 2024 spill closed local cockle beds for five weeks and remains under criminal investigation.
3 min

Comparisons across England, the US and the Netherlands show different cancer trends. Large percentage increases can still represent small absolute rates.
3 min

NASA attributes the colours in a September 27 satellite image to dissolved organic matter and mud stirred up by tides and currents.
2 min